In EMPACT-MI (Study to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction), the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin reduced heart failure (HF) events among patients with acute myocardial infarction (MI) and an increased risk for HF, although without improvement in all-cause mortality1–4. The gene discussed is SLC5A2; the disease is acute myocardial infarction.